Sun Pharma Advanced Research Company Limited has scheduled its 21st Annual General Meeting (AGM) for August 10, 2026, at 4:30 P.M. IST through video conferencing. The company has fixed August 3, 2026, as the cut-off date to determine shareholder eligibility for voting and attending the meeting. The Annual Report for the financial year 2025-26 was sent electronically to shareholders on July 16, 2026.

E-voting and Participation Details

Shareholders can exercise their voting rights through remote e-voting, facilitated by Central Depository Services (India) Limited (CDSL). The remote e-voting period commences at 9:00 A.M. IST on August 6, 2026, and concludes at 5:00 P.M. IST on August 9, 2026. Members who have not cast their votes remotely may vote during the AGM via the e-voting system, provided they are present through video conferencing.

Key Meeting Dates

Shareholders holding shares in physical form or those who have not registered their email addresses must follow specific instructions detailed in the AGM notice to access the e-voting facility. The company has mandated that physical shareholders update their KYC details, including PAN, nomination, and bank account information, with the Registrar and Transfer Agent.

Sun Pharma Advanced Research Company Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26 to the National Stock Exchange of India Ltd and BSE Limited. The filing, made pursuant to Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, details the company's adherence to the National Guidelines on Responsible Business Conduct (NGRBC). The report highlights the company's focus on integrating environmental, social, and governance (ESG) principles into its growth strategy as a clinical-stage biopharmaceutical organization.

General Disclosures and Operations

The company reported a total workforce of 466 employees for FY 2025-26, comprising 369 male and 97 female staff. The permanent employee count stood at 279, while other than permanent employees numbered 187. The board of directors includes six members, with two women representing 33% of the board. Key management personnel consists of three individuals, with one woman. The company operates three R&D facilities nationally and one office internationally, serving markets in three states and two countries.

Financial and Capital Metrics

Sun Pharma Advanced Research Company Ltd reported a paid-up capital of ₹32,45,21,588. The company’s turnover for the year was ₹1,87,917 lakh, with a net worth of ₹1,33,359 lakh. The report notes that the company incurred losses during the three immediately preceding financial years; consequently, it was not required to spend on Corporate Social Responsibility (CSR) activities during FY 2025-26.

Environmental Performance

The company disclosed its energy consumption, reporting total energy consumption from non-renewable sources at 18,772 GJ for FY 2025-26, a decrease from 20,600 GJ in the previous year. Water withdrawn totaled 28,891 KL, down from 30,011 KL in FY 2024-25. The company achieved Zero Liquid Discharge by reusing treated water for gardening. Greenhouse gas emissions included 27 metric tonnes of CO2 equivalent for Scope 1 and 3,108 metric tonnes for Scope 2. Total waste generated was 43 metric tonnes, of which 34 metric tonnes were recycled.

Governance and Stakeholder Engagement

The company identified material responsible business conduct issues, including data integrity and security, disruptive climate change events, and talent retention. It maintains grievance redressal mechanisms for shareholders and employees, recording one shareholder complaint in FY 2025-26 which was resolved. The board and key management personnel received 100% coverage in training and awareness programs covering all nine NGRBC principles. The company confirmed compliance with applicable environmental laws and regulations.

Subsidiary Information

As of March 31, 2026, the company’s subsidiaries include SPARCLIFE Inc. and Genokine Biotech Limited, which was incorporated as a wholly owned subsidiary on July 4, 2025. Both subsidiaries participate in the company's Business Responsibility initiatives.